GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences for $945 million in cash. SOFIE operates 15 U.S. contract-manufacturing sites with 21 cyclotrons. The transaction remains subject to closing conditions and regulatory approvals, with completion expected in the first half of 2027.
GLOBAL IMAGING BRIEF
PET imaging depends on time-sensitive tracer production and distribution. If completed, the deal would give GE HealthCare a larger U.S. last-mile manufacturing network; until closing, supply-chain integration remains prospective.
Original source
This brief is an original summary based on the cited public source.